TLR2 and neoplasm: This approach has been investigated in a mouse model of melanoma, where the combination of a TLR2-neutralizing antibody with cytosine-phosphate-guanine (CpG) oligodeoxynucleotides able to activate TLR9 and initiate anti-tumor immune responses acted synergistically to exert a potent anti-metastatic activity [137].